NEOCER is a MedTech / Biotechnology startup developing a portable genetic-analysis system aimed at supporting the early detection of cancer through microRNA (miRNA) analysis.
The core idea is to make cancer-related molecular screening more accessible by analyzing biological samples that can be collected with relatively low invasiveness, potentially including saliva, blood, and other biological fluids.
MicroRNAs are very small, non-coding RNA molecules that play an important role in regulating gene expression. Changes in specific microRNA patterns have been investigated as potential biomarkers associated with different diseases, including various cancers.
NEOCER's proposed system would:
1. Collect a biological sample
The system is intended to work with easily obtainable samples, reducing the need for complicated procedures.
2. Analyze microRNA profiles
The device analyzes selected microRNA biomarkers and looks for molecular patterns associated with cancer.
3. Identify abnormal patterns
The system compares the detected molecular profile against established patterns that may indicate an increased risk or potential presence of cancer.
4. Provide an early screening indication
Instead of waiting until symptoms become apparent, the technology aims to support earlier identification of potential cancer-related indicators.
5. Enable regular screening
Because the concept is designed around a portable and relatively accessible system, it could potentially support more frequent monitoring and screening.
One of the major challenges in cancer management is that early detection can significantly influence treatment options and outcomes. However, conventional cancer diagnostic procedures can be expensive, time-consuming, invasive, or dependent on specialized laboratories and medical infrastructure.
NEOCER's concept attempts to address this gap by moving part of the molecular screening process toward a portable, accessible, and potentially rapid testing platform.
Visit NEOCER WebSite
